Business Context and Reporting Period
This Form 8-K is a current report filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on May 11, 2011. The filing addresses corporate governance changes, specifically the appointment of a new director to fill a vacancy on the Board of Directors and the Audit Committee.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation arrangements rather than financial performance.
Material Changes
- Director Resignation: Odysseas D. Kostas resigned from the Board and Audit Committee on May 5, 2011.
- Director Appointment: The Board approved the appointment of David A. Ramsay to fill the vacancy, effective June 15, 2011, following the annual meeting of stockholders.
- Independence Status: Mr. Ramsay is designated as an "independent director" and meets eligibility standards for audit committee service.
Compensation and Outlook
Under the Company's director compensation policy, Mr. Ramsay's compensation includes:
- A quarterly retainer of $5,000 (pro-rated for Q2 2011).
- $1,000 for each Board or Board committee meeting attended.
- Eligibility for an "inducement option" and an "annual option" to purchase shares of common stock.
The filing contains no guidance, outlook, risk factors, or discussion of unusual items beyond the standard disclosure of the director appointment.
Investor Verification Checklist
- Verify the exact effective date of David A. Ramsay's appointment (June 15, 2011).
- Review the definitive proxy statement for the annual meeting (available at proxydocs.com) for full details on the director compensation policy.
- Confirm the independence status of the new director against NYSE Amex LLC Company Guide standards.
- Note that this filing does not contain financial data; refer to the most recent 10-Q or 10-K for financial metrics.